Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Express Scripts
Harvard Business School
Johnson and Johnson
McKinsey

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR ENSTILAR


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Enstilar

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02858713 ↗ Adherence in Topical Treatment of Psoriasis Completed Odense University Hospital Phase 4 2017-01-09 Medical adherence to topical corticosteroid products in psoriasis patients is a main determinant for poor treatment effect. The investigators aim to test if a multifaceted intervention delivered in an app (MyPso QualityCareTM owned by Leo Pharma) for smartphones combined with an Electronic Monitor (EM) (Teslo) can improve medical adherence among psoriasis patients treated with a topical calcipotriol/betamethasone dipropionate foam combination (Cal/BD) (Enstilar©). The study is classified as a phase 4 study, since it is studied if improved use of Enstilar© results in improved treatment outcomes. Link to published study protocol: https://bmcdermatol.biomedcentral.com/articles/10.1186/s12895-018-0071-3 Link to published results from the study: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.16667
NCT02881346 ↗ Efficacy and Tolerability of Enstilar® in Daily Practice Completed LEO Pharma 2016-09-01 This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities. In addition the profiles of patients prescribed Enstilar® will be described, and preceeding, concomitant and follow-up management will be mapped. The study will be conducted in about 100 dermatology clinics all over Germany,
NCT02935582 ↗ PSOREAL - Managing PSOriasis in the REAL World Completed LEO Pharma 2017-01-01 Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam fixed combination product Enstilar® (calcipotriol/betamethasone dipropionate).
NCT03080545 ↗ Enstilar in Combination With Biologic Agents Completed LEO Pharma Phase 4 2017-05-01 Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Enstilar

Condition Name

Condition Name for Enstilar
Intervention Trials
Psoriasis 7
Plaque Psoriasis 4
Psoriasis Vulgaris 3
Nail Psoriasis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Enstilar
Intervention Trials
Psoriasis 16
Connective Tissue Diseases 1
Erythema Multiforme 1
Skin Diseases, Papulosquamous 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Enstilar

Trials by Country

Trials by Country for Enstilar
Location Trials
United States 27
Denmark 2
Germany 1
United Kingdom 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Enstilar
Location Trials
Kentucky 4
New Jersey 4
New York 2
South Carolina 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Enstilar

Clinical Trial Phase

Clinical Trial Phase for Enstilar
Clinical Trial Phase Trials
Phase 4 11
Phase 3 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Enstilar
Clinical Trial Phase Trials
Completed 8
Recruiting 4
Unknown status 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Enstilar

Sponsor Name

Sponsor Name for Enstilar
Sponsor Trials
LEO Pharma 4
Psoriasis Treatment Center of Central New Jersey 4
Derm Research, PLLC 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Enstilar
Sponsor Trials
Other 14
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Boehringer Ingelheim
Harvard Business School
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.